A single-centre 10-year experience with Candida bloodstream infections

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 20, Issue 2, 2009, Pages 45-50

  Labbé, Annie Claude ^a,b   Pépin, Jacques ^c   Patiño, Carlos ^a   Castonguay, Stéphanie ^b   Restieri, Christiane ^a   Laverdiere, Michel ^a,b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Antifungals; Bloodstream infections; Canada; Candida infections

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDEMIA; CATHETER; FEMALE; FUNGUS ISOLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; OUTPATIENT;

EID: 66949112931     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/731070     Document Type: Article

References (30)

1. Krause W, Matheis H, Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet 1969;1:598-599
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317 (Pubitemid 39050477)
3. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-630
4. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-1079
5. Rodriguez D, Almirante B, Park BJ, et al. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J 2006;25:224-229 (Pubitemid 43379062)
6. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for Candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001;33:177-186 (Pubitemid 32643332)
7. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of Candidaemia in Europe: Results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004;23:317-322 (Pubitemid 38669942)
8. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519-1527
9. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298-1302 (Pubitemid 34279892)
10. Marichal P, Koymans L, Willemsens S, et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (Reading, England) 1999;145:2701-2713 (Pubitemid 29485885)
11. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-1277
12. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: Trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002;40:3551-3557
13. Taylor GD, Buchanan-Chell M, Kirkland T, McKenzie M, Wiens R. Trends and sources of nosocomial fungaemia. Mycoses 1994;37:187-190
14. Karlowsky JA, Zhanel GG, Klym KA, Hoban DJ, Kabani AM. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn Microbiol Infect Dis 1997;29:5-9.
15. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. Epidemiology, treatment and outcome of candidemia: A five-year review at three Canadian hospitals. Mycoses 2002;45:141-145 (Pubitemid 34743916)
16. St-Germain G PR, Laverdiere M. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec, Canada: Report of 453 case from 2003-2005. Can J Infect Dis Med Microbiol 2008;19:55-62.
17. National Committee for Laboratory Standards. Reference method for broth dilution antifungal susceptibility of yeasts. Approved Standards M27-A 1997; National Committeee for Laboratory Standards, Wayne, PA.
18. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: A 5 year population-based assessment. J Antimicrob Chemother 2005;56:532-537
19. Al-Rawahi G, Roscoe D. Candidemia: epidemiology, risk factors,and incidence of mixed candidemia in a Canadian tertiary health centre. Can J Infect Dis Med Microbiol 2008;19:113.
20. Kuhn DM, Mikherjee PK, Clark TA, et al. Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis 2004;10:1074-1081
21. Clark TA, Slavinski SA, Morgan J, et al. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 2004;42:4468-4472
22. Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: Results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005;43:1829-1835
23. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-1128 (Pubitemid 127774267)
24. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309-316 (Pubitemid 30049062)
25. Wingard JR. Importance of Candida species other than C albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-125
26. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: A case-case-control study. Antimicrob Agents Chemother 2005;49:4555-4560
27. Kartsonis N, Killar J, Mixson L, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: Relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005;49:3616-3623 (Pubitemid 41233008)
28. Hernandez S, Lopez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: Correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004;48:1382-1383 (Pubitemid 38405501)
29. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006;57:705-708
30. Jensen J, Munoz P, Guinea J, Rodriguez-Creixems M, Pelaez T, Bouza E. Mixed fungemia: Incidence, risk factors, and mortality in a general hospital. Clin Infect Dis 2007;44:e109-14.